Research Article
Ultrafast quantitative MS-based method for ceritinib analysis in human plasma samples from clinical trial
Published Online:6 Mar 2015https://doi.org/10.4155/bio.14.292
Abstract
Aim: An ultrafast, sensitive, selective and robust LDTD-APCI-MS/MS method was developed for the quantification of ceritinib in human plasma. Results: Samples were protein precipitated using acetonitrile containing [13C6]-ceritinib as internal standard. The assay was validated over a concentration range from 5.00 to 1000 ng/ml. Intra- and inter-day precision and accuracy met acceptance from EMA and US FDA guidelines. The normalized recovery was 69%, whereas no carryover and matrix effects were observed. The method was applied to clinical samples and resultant data were consistent with the LC–ESI–MS/MS reference method. Conclusion: The new assay is suitable for ceritinib quantification in clinical trials, whereas the analysis time is significantly reduced to 10 s.
Papers of special interest have been highlighted as: • of interest; •• of considerable interest
References
- 1 Cancer statistics, 2008. CA Cancer J. Clin. 58(2), 71–96 (2008).
- 2 EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin. Cancer. Res. 14(13), 4275–4283 (2008).
- 3 EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am. J. Pathol. 174(2), 661–670 (2009).
- 4 Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulf onyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J. Med. Chem. 56(14), 5675–5690 (2013).• Describes the in vitro activity of ceritinib.
- 5 Ceritinib in ALK-rearranged non-small-cell lung cancer. N. Engl. J. Med. 370(13), 1189–1197 (2014).•• First publishable results of clinical trial with ceritinib.
- 6 . Accelerating high quality bioanalytical LC/MS/MS assays using fused-core columns. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 878(25), 2307–2313 (2010).
- 7 . The use of partially porous particle columns for the routine, generic analysis of biological samples for pharmacokinetic studies in drug discovery by reversed-phase ultra-high performance liquid chromatography–tandem mass spectrometry. J. Pharm. Biomed. Anal. 49(1), 100–107 (2009).
- 8 . Laser diode thermal desorption-positive mode atmospheric pressure chemical ionization tandem mass spectrometry for the ultra-fast quantification of a pharmaceutical compound in human plasma. J. Pharm. Biomed. Anal. 54(5), 1088–1095 (2011).
- 9 Laser diode thermal desorption atmospheric pressure chemical ionization tandem mass spectrometry applied for the ultra-fast quantitative analysis of BKM120 in human plasma. Anal. Bioanal. Chem. 406(22), 5413–5423 (2014).•• First publishable results involving LDTD–APCI for the measurement of clinical samples.
- 10 . Ultra-fast cyclosporin A quantitation in whole blood by laser diode thermal desorption-tandem mass spectrometry; comparison with high performance liquid chromatography-tandem mass spectrometry. Anal. Chim. Acta. 805, 80–86 (2013).• Presents the comparative data between conventional LC–MS/MS method and LDTD–APCI–MS/MS.
- 11 . Determination of paracetamol in mouse, rat and dog plasma samples by laser diode thermal desorption-APCI-MS/MS. Bioanalysis 4(11), 1327–1335 (2012).
- 12 . Determination of metformin in mouse, rat, dog and human plasma samples by laser diode thermal desorption/atmospheric pressure chemical ionization tandem mass spectrometry. J. Pharm. Biomed. Anal. 53(3), 740–744 (2010).
- 13 Guidance for Industry. Bioanalytical Method Validation, US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (2001). www.fda.gov/CVM.
- 14 European Medicines Agency, Committee for Medicinal Products for Human Use, Guideline on bioanalytical method validation (2011). www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf.
- 15 . Liquid chromatography tandem mass spectrometry method for the quantitative analysis of ceritinib in human plasma and its application to pharmacokinetic studies. Anal. Bioanal. Chem. 406(28), 7389–7396 (2014).•• First Reportable LC–MS/MS-based method for the quantitative analysis of ceritinib in human samples.
- 16 . Measuring agreement in method comparison studies. Stat. Methods. Med. Res. 8(2), 135–160 (1999).
